Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.41)
# 334
Out of 5,090 analysts
233
Total ratings
44.34%
Success rate
27.59%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $9.35 | +103.21% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.71 | +175.55% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $48.92 | -22.32% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $93.29 | +64.00% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $45.68 | +37.92% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $21.33 | +275.06% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $36.38 | +188.62% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $77.26 | +52.74% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $80.38 | -7.94% | 2 | Aug 27, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $6.28 | +75.16% | 1 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $5.77 | +177.30% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 | $8.90 | +12.36% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $26.89 | +11.57% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $22.26 | +263.88% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.05 | +38.61% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $51.37 | +139.44% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.98 | +2,161.31% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.06 | +239.81% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $19.85 | +25.94% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $29.45 | +127.50% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $9.90 | +112.12% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.38 | +166.46% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.73 | +114.48% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.83 | +501.09% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.88 | +269.23% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.20 | +1,066.67% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.23 | +956.91% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.43 | +1,368.53% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.72 | +248.84% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $2.05 | +875.61% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.89 | +491.26% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.25 | +71,900.00% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $27.46 | +1,356.66% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.20 | +6,983.33% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.77 | +2,558.79% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.48 | +7,158.06% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.22 | +801.64% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.32 | +4,445.45% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.11 | +8,008.11% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.12 | +224,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $5.17 | +58,700.77% | 1 | Jan 9, 2020 |
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $9.35
Upside: +103.21%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.71
Upside: +175.55%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $48.92
Upside: -22.32%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $93.29
Upside: +64.00%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $45.68
Upside: +37.92%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $21.33
Upside: +275.06%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $36.38
Upside: +188.62%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $77.26
Upside: +52.74%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $80.38
Upside: -7.94%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $6.28
Upside: +75.16%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.77
Upside: +177.30%
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $8.90
Upside: +12.36%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $26.89
Upside: +11.57%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $22.26
Upside: +263.88%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $5.05
Upside: +38.61%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $51.37
Upside: +139.44%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.98
Upside: +2,161.31%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.06
Upside: +239.81%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.85
Upside: +25.94%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $29.45
Upside: +127.50%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $9.90
Upside: +112.12%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.38
Upside: +166.46%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.73
Upside: +114.48%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.83
Upside: +501.09%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.88
Upside: +269.23%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.20
Upside: +1,066.67%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.23
Upside: +956.91%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.43
Upside: +1,368.53%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.72
Upside: +248.84%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $2.05
Upside: +875.61%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.89
Upside: +491.26%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.25
Upside: +71,900.00%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $27.46
Upside: +1,356.66%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.20
Upside: +6,983.33%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.77
Upside: +2,558.79%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $2.48
Upside: +7,158.06%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.22
Upside: +801.64%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.32
Upside: +4,445.45%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.11
Upside: +8,008.11%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.12
Upside: +224,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $5.17
Upside: +58,700.77%